Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Desperate patients get access to experimental Lab-Made vessels

NCT ID NCT07141641

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: Humacyte, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times

Summary

This program offers individual patients with vascular disease or end-stage kidney disease on dialysis access to an experimental lab-grown blood vessel (ATEV) when all other treatments have failed and they cannot join a clinical study. The goal is to provide a potential option for those with no alternatives. The program is currently temporarily unavailable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VASCULAR DISEASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

acellular tissue engineered vessel (ATEV)

What this could lead to

If successful, this could provide a new option for patients with vascular disease or on dialysis who have run out of standard treatments.

What could go wrong

This is an expanded access program, not a formal trial, so evidence is limited. The vessel may fail or cause complications, and long-term benefits are uncertain.

Conditions

The condition(s) this trial relates to.

end stage renal failure vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.